The primary objective of the study is to evaluate the pharmacokinetics (PK) of teprotumumab after a single intravenous (IV) infusion of teprotumumab in healthy Chinese participants.

Inclusion Criteria:

1. Participant has provided informed consent.
2. Participants must be a resident in mainland China, and of Chinese ancestry (participants whose parents within 3 generations are of Chinese ancestry).
3. Male or female participants, between 18 and 60 years of age (inclusive). Female participants must be of nonchildbearing potential.
4. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations.
5. Body mass index between 18 and 27 kg/m^2 (inclusive) and minimum weight of 55 kg .

Exclusion Criteria:

1. History or evidence of clinically significant disorder, condition, or disease.
2. History of diabetes. (regardless of type with the exception of history of gestational diabetes). Hemoglobin A1C greater than or equal to 6.5% (greater than or equal to 48 mmol/mol).
3. Fasting glucose level (after at least an 8-hour fast) > 126 mg/dL (> 7 mmol/L).
4. History of or ongoing hearing impairment.
5. History of any autoimmune disease, inflammatory bowel disease, or TED.
6. History or evidence of ECG-findings.
7. Systolic blood pressure ≥ 140 mmHg or < 90 mmHg, or diastolic blood pressure ≥ 90 mmHg or < 50 mmHg, or pulse > 100 bpm or < 50 bpm , at screening or check-in.
8. History of relevant drug and/or food allergies.
9. Poor peripheral venous access and/or unable to receive IV infusion therapy.
10. Estimated glomerular filtration rate less than 90 mL/min/1.73 m2.
11. Active liver disease or hepatic dysfunction.
12. History of a medical condition associated with an increased risk of bleeding.
13. History of any major surgery within 6 months.
14. History of alcoholism or drug/chemical abuse within 1 year prior to check-in.
15. Use of tobacco- or nicotine-containing products within 6 months prior to check-in.
16. Positive test for illicit drugs and/or tetrahydrocannabinol/cannabinoids at check-in.
17. Female participants with a positive serum pregnancy test.
18. Female participants who are lactating/breastfeeding.
19. Male participants with partners who are pregnant.
20. Unwilling to adhere to contraceptive requirements.
21. Participant has received a dose of an investigational drug within the past 90 days.
22. Have previously completed or withdrawn from this study or any other study investigating teprotumumab or have previously received the investigational product.

De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.